Pre-earnings brief
Reports
Thu, Jul 30, 2026
Est. EPS
$1.51
Est. revenue
$13.3B
Implied move
±12.6%
EPS beat rate
100%
Sanofi (SNY) is a global healthcare company focused on pharmaceuticals and vaccines. With a market cap of $96 billion, it plays a significant role in addressing various health challenges, including chronic diseases and vaccines, making it a key player in the healthcare sector.
Last quarter
In the last quarter, Sanofi reported strong earnings, exceeding expectations with a notable EPS surprise. The company continued to focus on innovation and expanding its product pipeline.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+120.71%
Avg 1-day reaction
+1.51%
Analysts expect Sanofi to deliver solid earnings this quarter, with a consensus EPS of $1.51 and revenue of $13.3 billion. The market is looking for continued growth in key therapeutic areas.
Bull case
If Sanofi beats earnings expectations, it could signal strong demand for its products and effective cost management, potentially boosting investor confidence.
Bear case
Conversely, if the company misses estimates or provides weak guidance, it may raise concerns about its growth trajectory and market competitiveness.
Key metrics to watch
EPS
$1.51Earnings per share (EPS) is a crucial indicator of profitability and will show how well Sanofi is managing costs and generating income.
Revenue
$13.3BTotal revenue reflects the company's overall sales performance and market demand for its products.
The print will turn on these.
Q1
Will Sanofi's EPS exceed the consensus estimate of $1.51?
A beat on EPS could indicate strong operational efficiency and robust demand for its products, which would be positively received by the market.
Q2
What guidance will Sanofi provide regarding future revenue growth?
Investors will closely watch for any forward-looking statements that could impact growth expectations and stock performance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±7.0%
Why consensus could be wrong
The consensus may underestimate Sanofi's ability to leverage its innovative pipeline, which could lead to higher-than-expected revenue growth.
Supporting evidence
Sanofi's recent investments in R&D could yield new products that drive sales.
The company's strong historical performance in beating EPS estimates suggests it may continue this trend.
Options pricing indicates a significant expected move, reflecting investor uncertainty that could be resolved positively.
Key risk
If Sanofi announces a new product approval or significant partnership, it could dramatically shift market expectations.
Pre-commit to what would confirm each case.
The market is debating whether Sanofi can maintain its growth trajectory amidst competitive pressures and market challenges.
Bull confirmed if
An EPS of $1.60 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $1.40 would raise concerns about profitability and growth prospects.
What the market is pricing for the move.
Implied Move
±12.65%
Historical Avg
±3.1%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.
Options are pricing ±12.6% while SNY has averaged ±3.1% over the last 8 prints — setup is pricing rich.
30d HV
20.5%
Smart-money positioning from the most recent 13F filings.
Institutional
8.02%
of float
Insider
0.00%
of float
Holders
847
institutions
Top Holders· as of Jun 2026
Dodge & Cox Inc.
28,088,274 sh · $1.1B
10.54%
-4.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Sanofi beats expectations, history suggests a potential stock increase of around +1.5%, confirming strong demand and operational efficiency.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
Should the company miss earnings expectations, history suggests a potential decline of around -3.1%, raising concerns about future growth.
The lines on the call that would change the story.
Morgan Stanley
10,702,527 sh · $430.2M
4.02%
-14.5%
Fisher Asset Management, LLC
10,627,088 sh · $427.2M
3.99%
-7.1%
Bank of America Corporation
8,008,572 sh · $321.9M
3.00%
-15.6%
Invesco Ltd.
6,798,961 sh · $273.3M
2.55%
2.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.